Form 4: Vor Biopharma Director Matthew Patterson Receives Significant Stock Option Grant

Matthew R. Patterson, a Director at Vor Biopharma Inc., was granted 30,000 stock options as part of the company's non-employee director compensation policy.

Summary

• Matthew R. Patterson, a Director of Vor Biopharma Inc. (VOR), was granted 30,000 stock options on May 22, 2025.
• The stock options have an exercise price of $0.1868 per share.
• These options are set to expire on May 21, 2035.
• The shares underlying the option will vest and become exercisable on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Patterson's continued service as a director through the vesting date.
• This grant was made pursuant to the Issuer's non-employee director compensation policy.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of alignment between the board and shareholder interests, and is a standard, expected practice. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options to Director Matthew R. Patterson aligns his interests with shareholders, incentivizing long-term company performance.
• The option grant is part of a standard non-employee director compensation policy, indicating a structured and transparent approach to director remuneration.

Future Outlook

The stock option grant incentivizes the director's continued service and aligns his long-term interests with the company's performance, subject to the specified vesting conditions.

Industry Context

This is a routine insider transaction for a biotechnology company, where equity compensation is a common practice to attract and retain qualified board members, particularly for non-employee directors, aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• Equity compensation, such as stock options, for non-employee directors is a standard practice across the biotechnology and broader corporate sectors, aiming to align director incentives with shareholder returns.
• The specific exercise price and number of options granted would typically be benchmarked against peer companies of similar market capitalization and stage of development within the biotech industry, though this document does not provide such comparative data for specific companies or projects.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing long-term stock performance.
• Employees: No direct impact on employees, but reflects standard compensation practices for leadership.

Next Steps

• The granted options will vest on the earlier of May 22, 2026, or the Issuer's next annual meeting of stockholders, provided the director continues service.
• The director may exercise the options at the specified price of $0.1868 per share once they vest and before the expiration date of May 21, 2035.

Key Dates

Keywords

Vor Biopharma, VOR, Stock Option, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction, Matthew Patterson